Human onchocerciasiscommonly known as river blindnessis one of the most devastating yet neglected tropical diseases, leaving many millions in Sub-Saharan Africa blind and/or with chronic disabilities. Attempts to eliminate onchocerciasis, primarily through the mass drug administration of ivermectin remains challenging and has been heightened by the recent news that drug-resistant parasites are developing in some populations after years of drug treatment. Needed, and needed now, in the fight to eliminate onchocerciasis are new tools, such as preventive and therapeutic vaccines. This review summarizes the progress made to advance the onchocerciasis vaccine from the research lab into the clinic.
Why a vaccine against Onchocerca volvulus is needed
However, it remains unlikely that onchocerciasis can be eliminated as a public health 57 problem entirely through ivermectin mass treatments. The reasons for this observation 58 have been reviewed recently, and include the inability to implement large-scale 59 treatment programs in areas that are co-endemic for loiasis, and the potential for 60 emerging anthelminthic drug resistance [2] . Recent genome-wide analyses revealed 61 genetic variation that significantly differentiated O. volvulus parasites that are good 62 responders to treatment with ivermectin to O. volvulus parasites that are sub-optimal 63 responder and taken from individuals in Ghana and Cameroon that have experienced 64 repopulation of the skin microfilariae earlier/more extensively after ivermectin treatment 65 than expected [3] . 66
67
In addition, disease modeling studies show that transmission interruption and 68 elimination will require routine and regular quantum reductions in O. volvulus 69 microfilariae in the skin and subcutaneous tissues following each round of MDA, but 70 such targets are seldom achieved [2] . The African Programme for Onchocerciasis 71
Control predicted in 2015 that to achieve elimination 1.15 billion treatments will have 72 needed to be administered until 2045 [4] . Such estimates indicate that onchocerciasis 73 may not be eliminated for decades using current approaches. 74
75
To accelerate elimination and advance towards the major targets of the 2012 London 76
Declaration for NTDs 77
(http://unitingtocombatntds.org/sites/default/files/document/london_declaration_on_ntds. 78 pdf), there is an effort to develop new and improved control tools. These include better 79 diagnostics, small-molecule drugs and vaccines that can improve surveillance and 80 achieve longer and more sustained reductions in host microfilarial loads. There is also 81 a need for better safety profiles for interventions used in loiasis co-endemic areas of 82 Africa. Individuals who have high blood levels of Loa loa microfilariae, a filarial infection 83 that usually does not cause clinical disease, and receive ivermectin as part of the MDA 84 programs to eradicate lymphatic filariasis and onchocerciasis may develop a severe 85 inflammatory reaction that can result in encephalopathy, and rarely death. In 2015, an 86 international consortium launched a new global initiative, known as TOVA -The 87 the adult worms and microfilaria associated with patent infection [ properties, Ov-GAPDH, which was cloned using immunoscreening, has been recently 200 reported [23] . Thus out of a total of 16 vaccine candidates, 12 were identified by 201 immunoscreening and 4 were identified using other approaches as illustrated in Figure  202 1. Below we will describe the 8 vaccine candidates chosen to be studied more in depth 203
for their ability to insure protection against infection. Table 1 ). The added scoring was 234 based on the following criteria: (1) score 0.2 was given to those that are nematode or 235 parasite specific with or without known function (for example Ov-CPI-2 (cystatin), Ov-236 RBP-1 (retinoid binding protein) or Ov-CHI-1 (chitinase); (2) score 0.2 was given to 237 those in which localization of the corresponding native proteins in L3 and/or mL3 by 238 immunoelectron microscopy was in one or more regions that are also recognized by 239 antibodies from protected humans and/or also from xL3 immunized and protected mice 240 and Ov-B20) for which we propose to conduct extensive preclinical evaluation and 260 further selection. Those selected are ranked between a total score of 4.0 to 2.6 261 (Supplement Table 1 ). Those of the original 15 rOvAgs that were not selected were only 262 ranked at a total score of 1.0 to 1.6. The disappointing results obtained many times during human proof of concept clinical 312 trials, continue to highlight the challenges and limitations of how to best predict whether 313 a vaccine candidate translates successfully from animal testing into humans [58, 59] . 314
Many articles call for a change in paradigm from an empirical development strategy to a 316 rational vaccine design [60] [61] [62] . Amongst the parameters driving decisions during the 317 development of new vaccine targets, the current consensus is that antigen selection 318 and optimization represents the foundation in vaccine design. In addition, it is essential 319 to have available appropriate preclinical models, but it is also crucial to have optimal 320 vaccine formulations, adjuvants and delivery strategies. These are essential elements to 321 target the appropriate immune mechanisms of protection [63] . This is especially 322 important when developing vaccines for infectious diseases, such as for onchocerciasis, 323 because unfortunately scientific advances and tools are still trailing and there is also a 324 need for safety and efficacy studies to be done more quickly, with more certainty and at 325 lower costs. or surrogate endpoints for protection will be necessary and essential [60] . 359
360
The current accumulation of molecular data and expansion of filarial parasite RNA and 361 DNA databases, as well as proteomic datasets, has already provided a fresh start by 362 permitting a more rational approach to vaccine candidate discovery [ IgG3 reactivity with little-to-no IgE reactivity. Notably, four of these antigens 389 (OVOC10819, OVOC5395, OVOC11598 and OVOC12235) are highly expressed during 390 the development of the early stages of the infective stage larvae, L3, in the human host; 391 these would be worthy candidates for testing their efficacy in a preventative vaccine 392 model of infection. Interestingly, the two other proteins (OVOC8619 and OVOC7083) 393 are highly expressed by the microfilariae and were mostly recognized by sera from the 394 putatively immune individuals who never developed a patent infection with 395 microfilaridermia; these would be worthy to be tested as vaccine candidates for a 396 therapeutic vaccine [71] . 397
398
The initial objective for the Onchocerca vaccine was to identify candidate antigens for a 399 prophylactic vaccine to be administered to children under the age of five who have not 400 yet had access to MDA with ivermectin (Table 1) whether a vaccine candidate is likely to be both safe and effective is very challenging 440 using conventional approaches alone, especially as we lack animal models that 441 recapitulate the pathology seen in human onchocerciasis. 442
443
Traditional statistical approaches can be powerful at disentangling these immunological 444 events, but tend not to generalize well from model systems to humans. However, 445 machine learning techniques have been developed to improve generalizability by tuning 446 models to maximize prediction accuracy to independent test samples, and tend to deal 447 with large numbers of variables better than traditional statistical approaches [87, 88] . clinical phases of vaccine development (Fig. 2) . 456
457

Concluding remarks 458 459
Although it was previously considered that O. volvulus infections can be controlled using 460 only MDA with ivermectin, it is becoming increasingly clear that without additional 461 modalities such as drugs which kill or permanently sterilize the adult worms and/or a 462 
Final down selection:
Ov-103 , Ov-RAL-2 
